Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Universal Biosensors Inc's Business Segments
Universal Biosensors Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Transferred at Point in Time
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Transferred at Point in Time0%
- Coagulation Test Devices74.1%
- Wine Testing Products63.9%
- Laboratory Testing Services10.2%
- Veterinary Diabetes Product Member4.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Transferred at Point in Time | $ 1 | - |
| Coagulation Test Devices | $ 1 | 74.1% |
| Wine Testing Products | $ 1 | 63.9% |
2 more segments available
Sign in to unlock the full Universal Biosensors Inc dataset.
Revenue by Product & Service Category - FY
- Product0%
- Coagulation Test Devices74.1%
- Wine Testing Products63.9%
- Laboratory Testing Services10.2%
- Service10.2%
- Veterinary Diabetes Product4.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1 | - |
| Coagulation Test Devices | $ 1 | 74.1% |
| Wine Testing Products | $ 1 | 63.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Universal Biosensors Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Transferred at Point in Time0%
- Coagulation Test Devices74.1%
- Wine Testing Products63.9%
- Laboratory Testing Services10.2%
- Veterinary Diabetes Product Member4.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Transferred at Point in Time | $ 1 | - |
| Coagulation Test Devices | $ 1 | 74.1% |
| Wine Testing Products | $ 1 | 63.9% |
2 more segments available
Sign in to unlock the full Universal Biosensors Inc dataset.
Description of Universal Biosensors Inc
Universal Biosensors Inc. is a global leader in the development and supply of advanced electrochemical sensor platforms. The company specializes in the design, development, and manufacture of in-vitro diagnostics (IVD) and point-of-care (POC) biosensors. These biosensors are used in various medical applications such as blood glucose monitoring, blood coagulation testing, cardiac marker testing, and cholesterol testing.
Universal Biosensors focuses on developing biosensors that offer a high level of accuracy, reliability, and ease of use. The company's proprietary technology, based on a combination of enzyme chemistry, sophisticated instrument design, and miniaturized electronics, allows for highly sensitive and rapid measurements of biomarkers. This technology enables healthcare professionals and patients to obtain accurate test results quickly, facilitating timely diagnosis and monitoring of medical conditions.
The company's flagship biosensor platform is known as the proprietary Thin Film technology. This technology is considered a breakthrough in biosensor design as it allows for the creation of ultra-thin and highly flexible biosensors, providing exceptional performance and ease of integration into various diagnostic systems. The Thin Film technology also enables the development of cost-effective biosensors, making them more accessible to a wider range of healthcare providers and patients.
Universal Biosensors prides itself on its strong partnerships and collaborations with leading global companies in the healthcare and diagnostics industries. The company has established strategic alliances with multinational corporations, enabling it to leverage its expertise in biosensor technology and expand its market presence. These partnerships also contribute to the ongoing research and development efforts aimed at introducing innovative biosensor solutions to address the unmet needs of healthcare professionals and patients worldwide.
In addition to its focus on IVD and POC applications, Universal Biosensors is actively involved in research and development initiatives aimed at expanding the capabilities of biosensors. The company's scientific team works closely with renowned academic institutions and research organizations to explore new opportunities for biosensor applications. This collaborative approach ensures the constant advancement of biosensor technology and the development of new products that can revolutionize the healthcare industry.
Universal Biosensors is committed to meeting the highest standards of quality and regulatory compliance. The company operates in accordance with global regulatory guidelines and standards such as ISO 13485, ensuring the production of safe and effective biosensors for use in diagnostic testing. This commitment to quality has earned Universal Biosensors a strong reputation within the healthcare industry and has positioned the company as a trusted partner for healthcare providers worldwide.
Overall, Universal Biosensors Inc. is a leading global provider of advanced electrochemical sensor platforms specializing in IVD and POC biosensors. The company's cutting-edge technology, strong partnerships, and commitment to quality have made it a key player in the field of diagnostic testing, with the potential to significantly impact patient care and outcomes.
Universal Biosensors focuses on developing biosensors that offer a high level of accuracy, reliability, and ease of use. The company's proprietary technology, based on a combination of enzyme chemistry, sophisticated instrument design, and miniaturized electronics, allows for highly sensitive and rapid measurements of biomarkers. This technology enables healthcare professionals and patients to obtain accurate test results quickly, facilitating timely diagnosis and monitoring of medical conditions.
The company's flagship biosensor platform is known as the proprietary Thin Film technology. This technology is considered a breakthrough in biosensor design as it allows for the creation of ultra-thin and highly flexible biosensors, providing exceptional performance and ease of integration into various diagnostic systems. The Thin Film technology also enables the development of cost-effective biosensors, making them more accessible to a wider range of healthcare providers and patients.
Universal Biosensors prides itself on its strong partnerships and collaborations with leading global companies in the healthcare and diagnostics industries. The company has established strategic alliances with multinational corporations, enabling it to leverage its expertise in biosensor technology and expand its market presence. These partnerships also contribute to the ongoing research and development efforts aimed at introducing innovative biosensor solutions to address the unmet needs of healthcare professionals and patients worldwide.
In addition to its focus on IVD and POC applications, Universal Biosensors is actively involved in research and development initiatives aimed at expanding the capabilities of biosensors. The company's scientific team works closely with renowned academic institutions and research organizations to explore new opportunities for biosensor applications. This collaborative approach ensures the constant advancement of biosensor technology and the development of new products that can revolutionize the healthcare industry.
Universal Biosensors is committed to meeting the highest standards of quality and regulatory compliance. The company operates in accordance with global regulatory guidelines and standards such as ISO 13485, ensuring the production of safe and effective biosensors for use in diagnostic testing. This commitment to quality has earned Universal Biosensors a strong reputation within the healthcare industry and has positioned the company as a trusted partner for healthcare providers worldwide.
Overall, Universal Biosensors Inc. is a leading global provider of advanced electrochemical sensor platforms specializing in IVD and POC biosensors. The company's cutting-edge technology, strong partnerships, and commitment to quality have made it a key player in the field of diagnostic testing, with the potential to significantly impact patient care and outcomes.
Universal Biosensors Inc. (UBI) is a biotechnology company that specializes in developing and manufacturing advanced diagnostic tests using its proprietary biosensor technology. UBI focuses on point-of-care (POC) testing solutions that enable quick, accurate, and reliable results, enhancing the efficiency of medical diagnostics, particularly in the fields of diabetes management, infectious diseases, and other critical health conditions.
Segments
1. Point-of-Care Testing:
- This segment aims to provide rapid diagnostic tests that can be performed at the site of patient care without the need for laboratory facilities. UBI’s POC tests are instrumental for both healthcare professionals and patients, enabling immediate decision-making based on test results.
2. Laboratory Testing:
- UBI also works on tests that can be performed in laboratory settings. These tests may benefit from enhanced sensitivity and specificity, allowing for more detailed and complex analyses that are essential in thorough patient diagnostics.
3. Research and Development:
- The R&D segment focuses on innovation in biosensor technologies, enhancing current product lines, and developing new diagnostic applications. This includes partnerships with academic institutions and other companies to broaden the scientific base and technological capabilities.
Products and Services
1. Glucose Monitoring Solutions:
- UBI has developed advanced glucose monitoring systems aimed at diabetics. These products generally provide blood glucose results quickly, allowing patients to make immediate decisions regarding their insulin management.
2. Hemoglobin A1c Testing:
- UBI offers testing solutions for Hemoglobin A1c (HbA1c), which is a crucial marker for long-term glucose control. The ability to measure HbA1c in a point-of-care setting represents a significant advancement in diabetes management, enabling health professionals to evaluate patient control more effectively.
3. Infectious Disease Testing:
- The company works on multiple tests for infectious diseases, likely including assays that can swiftly identify pathogens, thus facilitating timely diagnosis and treatment. These products aim to help manage outbreaks and improve patient outcomes by providing healthcare professionals with rapid and reliable test results.
4. Custom Development Services:
- UBI provides custom development services for partners looking to create specialized biosensors tailored for specific applications. This may include diagnostic services for various conditions beyond the current product offerings, leveraging UBIs expertise in biosensor technology.
5. Regulatory Support:
- Assisting partners with regulatory submissions and compliance processes is crucial for the successful commercialization of diagnostic products. UBI supports regulatory pathways to ensure that tests meet the required standards for safety and efficacy.
6. Partnerships and Collaboration:
- UBI often collaborates with pharmaceutical companies, healthcare organizations, and regulatory bodies to broaden the applications of their technology. These partnerships can lead to the co-development of innovative diagnostic platforms and products.
Technical and Scientific Support:
- UBI offers ongoing technical and scientific support to clients using its diagnostic solutions, helping ensure proper usage and integration into clinical workflows. This service is key to user satisfaction and effective implementation in healthcare settings.
In summary, Universal Biosensors Inc. is focused on harnessing biosensor technology to transform medical diagnostics through rapid, point-of-care testing solutions. Their product offerings and services cater to critical healthcare needs across diabetes management and infectious diseases, underpinned by a commitment to continuous innovation and collaboration with partners in healthcare.
Segments
1. Point-of-Care Testing:
- This segment aims to provide rapid diagnostic tests that can be performed at the site of patient care without the need for laboratory facilities. UBI’s POC tests are instrumental for both healthcare professionals and patients, enabling immediate decision-making based on test results.
2. Laboratory Testing:
- UBI also works on tests that can be performed in laboratory settings. These tests may benefit from enhanced sensitivity and specificity, allowing for more detailed and complex analyses that are essential in thorough patient diagnostics.
3. Research and Development:
- The R&D segment focuses on innovation in biosensor technologies, enhancing current product lines, and developing new diagnostic applications. This includes partnerships with academic institutions and other companies to broaden the scientific base and technological capabilities.
Products and Services
1. Glucose Monitoring Solutions:
- UBI has developed advanced glucose monitoring systems aimed at diabetics. These products generally provide blood glucose results quickly, allowing patients to make immediate decisions regarding their insulin management.
2. Hemoglobin A1c Testing:
- UBI offers testing solutions for Hemoglobin A1c (HbA1c), which is a crucial marker for long-term glucose control. The ability to measure HbA1c in a point-of-care setting represents a significant advancement in diabetes management, enabling health professionals to evaluate patient control more effectively.
3. Infectious Disease Testing:
- The company works on multiple tests for infectious diseases, likely including assays that can swiftly identify pathogens, thus facilitating timely diagnosis and treatment. These products aim to help manage outbreaks and improve patient outcomes by providing healthcare professionals with rapid and reliable test results.
4. Custom Development Services:
- UBI provides custom development services for partners looking to create specialized biosensors tailored for specific applications. This may include diagnostic services for various conditions beyond the current product offerings, leveraging UBIs expertise in biosensor technology.
5. Regulatory Support:
- Assisting partners with regulatory submissions and compliance processes is crucial for the successful commercialization of diagnostic products. UBI supports regulatory pathways to ensure that tests meet the required standards for safety and efficacy.
6. Partnerships and Collaboration:
- UBI often collaborates with pharmaceutical companies, healthcare organizations, and regulatory bodies to broaden the applications of their technology. These partnerships can lead to the co-development of innovative diagnostic platforms and products.
Technical and Scientific Support:
- UBI offers ongoing technical and scientific support to clients using its diagnostic solutions, helping ensure proper usage and integration into clinical workflows. This service is key to user satisfaction and effective implementation in healthcare settings.
In summary, Universal Biosensors Inc. is focused on harnessing biosensor technology to transform medical diagnostics through rapid, point-of-care testing solutions. Their product offerings and services cater to critical healthcare needs across diabetes management and infectious diseases, underpinned by a commitment to continuous innovation and collaboration with partners in healthcare.